NYSE:JNJ 2 November 2025 - 6 December 2025

Johnson & Johnson heads into December 2025 as one of the market’s standout large‑cap healthcare performers, combining a 2025 share‑price surge with classic “defensive” traits like steady earnings and a long dividend track record—while still carrying a very real legal overhang from talc litigation.

Johnson & Johnson stock is trading close to its 52‑week high around the low‑$200s per share, giving the healthcare giant a market capitalization of roughly $500–505 billion.PortfoliosLab+1

Johnson & Johnson heads into the new trading week sitting just under all‑time highs, after a powerful rally that’s pushed the healthcare giant toward a $500 billion market value.FinancialContent+1

Johnson & Johnson stock has quietly turned into one of 2025’s big winners. After years of trading like a sleepy defensive name, JNJ has gone on an 11‑ to 13‑day winning streak, pushed its market capitalization to roughly $500 billion, and logged one of its strongest years since the mid‑1990s. Nai500

Johnson & Johnson is quietly turning into one of 2025’s standout mega‑cap stories. By this afternoon on Wednesday, November 26, J&J shares were trading around $207 per share, up modestly on the day and hovering near their all‑time highs.Macrotrends

Johnson & Johnson’s Q3 report and guidance boost have underpinned recent optimism. Excluding currency effects, total sales rose 6.8% to $23.99B, with key drugs like Darzalex and its autoimmune blockbusters driving growthts2.techreuters.com. Adjusted EPS of $2.80 beat forecasts, and management raised full-year 2025 product revenue guidance to $93.5–93.9Breuters.com. Such beats and raises were well-received: on Oct. 14 JNJ stock spiked ~2%, closing near $191ts2.tech. Analysts point out that JNJ now expects 2026 sales growth above 5%, reflecting confidence in its new drug launches and MedTech momentumts2.techinvesting.com. Even as the blockbuster Stelara loses exclusivity, JP Morgan calls J&J “one of the cleaner stories” in big pharma, given steady core growthreuters.com.